Medication info
Cirtan Tablet 160 mg (Valsartan)

Cirtan Tablet 160 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›160mg / 1 tablet
Manufacturer / importer
HLB Pharmaceuticals Co., Ltd.
Appearance
Oval film-coated tablet with a gray-orange color
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201802156 · Approved 2018.05.24 · Insurance code 647303380

Summary

Main use
Treatment of essential hypertension, reduction of the risk of death after myocardial infarction, and treatment of heart failure
Who takes it
Adults · Children
Adult dose
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Adults: The recommended dose, regardless of sex or race, is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be given concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. Patients with renal impairment: Creatinine clearance 20–50 mL/min: No dose adjustment is necessary. Creatinine clearance 10–20 mL/min: Start treatment with 40 mg of this medicine once daily. Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy of this medicine with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Over the next several weeks, increase the dose, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. 4. Patients with renal impairment: No dose adjustment is necessary if creatinine clearance is 10 mL/min or higher. However, there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis; do not administer this medicine to these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, it is preferable that the daily dose of this medicine not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
Essential hypertension — Children and adolescents under 18 years: Safety and efficacy have not been established. Heart failure — Children and adolescents under 18 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
HLB Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of essential hypertension, reduction of the risk of death after myocardial infarction, and treatment of heart failure

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
View approved original text

This medicine is mainly used for essential hypertension and heart failure. It is particularly suitable for heart failure patients (NYHA Class II to IV) who cannot use ACE inhibitors. Additionally, it helps reduce the risk of death in patients with impaired left ventricular function after myocardial infarction. Therefore, it plays a crucial role in controlling blood pressure, alleviating heart failure symptoms, and improving survival rates after myocardial infarction. This medicine is used to enhance cardiovascular health.

How to take

Adult dose

1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Adults: The recommended dose, regardless of sex or race, is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be given concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. Patients with renal impairment: Creatinine clearance 20–50 mL/min: No dose adjustment is necessary. Creatinine clearance 10–20 mL/min: Start treatment with 40 mg of this medicine once daily. Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy of this medicine with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Over the next several weeks, increase the dose, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. 4. Patients with renal impairment: No dose adjustment is necessary if creatinine clearance is 10 mL/min or higher. However, there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis; do not administer this medicine to these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, it is preferable that the daily dose of this medicine not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

Essential hypertension — Children and adolescents under 18 years: Safety and efficacy have not been established. Heart failure — Children and adolescents under 18 years: Safety and efficacy have not been established.

Precautions

This medicine can cause serious harm to the fetus, especially if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately if pregnancy is confirmed. People who are allergic to this medicine or its ingredients, women who are pregnant or may become pregnant, patients with severe liver disease or severely impaired kidney function should not take this medication. Elderly patients or those with high potassium levels, patients with slightly impaired liver function, and those with heart valve disease or cardiovascular diseases need to exercise special caution when using this medicine. This medicine may have a strong blood pressure-lowering effect, so when starting the medication or increasing the dosage, it should be done gradually to avoid symptoms of hypotension, and the patient’s condition should be closely monitored. Side effects such as dizziness, fatigue, cough, and indigestion may occur during treatment, and rarely serious allergic reactions, kidney function impairment, or hyperkalemia may develop; if any abnormal symptoms appear, immediate consultation with healthcare professionals is necessary. Additionally, caution is needed when taking this medication with other antihypertensives, diuretics, or potassium-sparing medications, as this may lead to dangerously high potassium levels in the blood. Pregnant or breastfeeding women are advised not to take this medication, and if absolutely necessary, they should consult with a healthcare professional. The safety and efficacy of this medication have not been established in children or adolescents under 18 years of age, so its use is not recommended. Overdose may result in severe hypotension or loss of consciousness, so immediate emergency treatment is required, and it should be kept out of reach of children.

Side effects

  • headache
  • dizziness
  • viral infection
  • upper respiratory tract infection
  • cough
  • diarrhea
  • fatigue
  • rhinitis
  • sinusitis
  • abdominal pain
Show 53 more
  • stomachache
  • nausea
  • pharyngitis
  • joint pain
  • hypotension
  • orthostatic dizziness
  • orthostatic hypotension
  • renal impairment
  • hyperkalemia
  • angioedema
  • heart failure
  • arrhythmia
  • drowsiness
  • atrial fibrillation
  • vomiting
  • constipation
  • thirst
  • loss of appetite
  • malaise
  • vascular edema
  • redness
  • itching
  • serum sickness
  • vasculitis
  • hepatitis
  • syncope
  • epistaxis
  • interstitial pneumonia
  • hypoglycemia
  • shock
  • loss of consciousness
  • rhabdomyolysis
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • vesicular dermatitis
  • decreased red blood cell volume
  • decreased hemoglobin
  • neutropenia
  • edema
  • weakness
  • insomnia
  • decreased libido
  • rash
  • myalgia
  • dyspepsia
  • anemia
  • tinnitus
  • hypertonia
  • reduced exercise capacity
  • confusion
  • chest pain
  • rigidity

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a tightly sealed container to prevent exposure to air and moisture, and it is important to maintain a temperature below 30 degrees Celsius. Keeping it in this way will safely preserve the effectiveness of the medication.

Appearance and packaging

Appearance

Oval film-coated tablet with a gray-orange color

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.